#4-83E. Biologics as a Shield: Preventing Relapse in Relapsing Polychondritis (Rheumatology, 2026)

Are you struggling to manage recurrent flares in patients with refractory relapsing polychondritis (RP)? In today's episode, we dive into the study "Association between biologic exposure and relapse incidence in relapsing polychondritis: a retrospective cohort study." This single-center retrospective study evaluated 55 adult patients with RP to determine if exposure to biologics, specifically TNF inhibitors and IL-6 receptor inhibitors, alters the incidence of disease relapse compared to periods without biologic therapy. The most crucial finding suggests that biologic exposure is associated with significantly lower relapse rates, highlighting its efficacy in preventing recurrent disease flares. While this provides a strong scientific rationale for incorporating biologics into the management of refractory cases, listeners must critically appraise the study's limitations. Notably, as a single-center retrospective analysis with a small sample size, the study is susceptible to confounding by indication, and the estimates regarding the risk of hospitalized infections remain imprecise. Nevertheless, these findings are highly relevant, offering physicians valuable evidence to guide treatment decisions and ultimately reduce the chronic flare burden in patients suffering from this rare and debilitating disease.

Citation: Nakayama Y, Shirakashi M, et al. Association between biologic exposure and relapse incidence in relapsing polychondritis: a retrospective cohort study. Rheumatology. 2026. DOI: 10.1093/rheumatology/keag305/8706703

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.